[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sinovac Life Sciences Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":190},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,65,90,110,136,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100643376","phase-3-a-phase--clinical-study-of-sna02-48-injection-100643376",false,"NCT07633119","A Phase Ⅲ Clinical Study of SNA02-48 Injection","A Multicenter, Randomized, Double-Blind, Active-Controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of SNA02-48 Injection in Populations With High-Risk Tetanus Exposure","Inclusion Criteria:\n\n1. Males or females aged 18 years and above;\n2. Participants who can understand and voluntarily sign the informed consent form;\n3. Participants with high-risk tetanus exposure;\n4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures from the time the participant signs the informed consent form until 6 months after administration, with no plans for sperm or egg donation.\n\nExclusion Criteria:\n\n1. Suspected or confirmed tetanus ;\n2. A history of previous tetanus infection;\n3. A known history of 3 or more doses of tetanus toxoid or vaccines containing tetanus toxoid, or fewer than 3 previous doses but with the last dose of tetanus toxoid or vaccines containing tetanus toxoid administered within 6 months prior to the administration of the investigational product;\n4. Known hypersensitivity to the investigational product (including excipients, HTIG, and other therapeutic monoclonal antibodies), or suffering from severe allergic diseases that, in the investigator's judgment, may impair the participant's safety; Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The primary objective of this clinical trial is to compare the efficacy and safety of SNA02-48 injection with Human Tetanus Immunoglobulin (HTIG) for tetanus prophylaxis.",[26],"Tetanus","NOT_YET_RECRUITING","2026-06-02",{"date":30,"type":31},"2026-06-08","ACTUAL",{"date":33,"type":20},"2026-06-28",{"date":35,"type":20},"2027-05-31",{"name":37,"class":38},"Sinovac Life Sciences Co., Ltd.","INDUSTRY",30,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100638032","phase-3-clinical-trial-of-pcv13-in-infants-aged-approximately-2-months-42-to-89-days-100638032","NCT07593924","Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)","A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Administered as a Series of 2 Infant Doses and 1 Toddler Dose in Healthy Infants","Inclusion Criteria:\n\n1. Health infants aged approximately 2 months (42 to 89 days)\n2. Have a parent\u002Flegal guardian who has provided written informed consent after being fully informed about the study.\n3. Be able to provide the vaccination records since birth.\n4. The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).\n\nExclusion Criteria:\n\n1. Previous vaccination of any licensed or investigational pneumococcal vaccine, or planned receipt during the study participation;\n2. Previous vaccination of vaccines containing the component of diphtheria, tetanus, pertussis, poliomyelitis, and\u002For Hib vaccine.\n3. Previous receipt of ≥2 doses of hepatitis B vaccine; or receipt of a single hepatitis B vaccine dose administered at \\>30 days old.\n4. History of severe adverse reaction to previous vaccinations and\u002For serious allergic reactions (eg, anaphylaxis) to any vaccine component.\n5. History of any laboratory confirmed pneumococcal bacterial pneumonia or invasive pneumococcal diseases caused by S pneumoniae.\n6. Premature infants (born before week 37 of gestation).\n7. Severe congenital malformations, developmental disorders, clinically significant genetic defects, malnutrition.\n8. Autoimmune diseases or immunodeficiency\u002Fimmunosuppression.\n9. Serious chronic diseases such as Down's syndrome, diabetes, sickle cell anemia, or neurological disorders.\n10. Abnormal coagulation functions (e.g., coagulation factor deficiency, blood coagulation diseases, platelet disorders).\n11. Received immunosuppressive for ≥14 days (e.g., prednisone equivalent of ≥2 mg\u002Fkg), or cytotoxic drug before enrollment, or plans to receive these treatments during the study participation.\n12. Received blood products before investigational vaccine inoculation, or plan to receive these treatments during study participation.\n13. Received other investigational drugs\u002Fvaccines before enrollment, or plan to receive investigational drugs\u002Fvaccines during study participation.\n14. Received live attenuated vaccines or nucleic-acid vaccines within 14 days before enrollment.\n15. Received subunit or inactivated vaccines within 7 days before enrollment.\n16. Acute diseases or acute exacerbations of chronic diseases within 7 days before enrollment.\n17. Axillary temperature ≥ 37.5°C before enrollment.\n18. Any other factors judged by the investigators as unsuitable for participation.",true,"42 Days","89 Days",{"count":51,"type":20},500,[23],"A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).\n\nThe objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.",[55],"Pneumococcal Infectious Diseases","2026-05-11",{"date":58,"type":31},"2026-05-18",{"date":60,"type":20},"2026-05",{"date":62,"type":20},"2027-07",{"name":37,"class":38},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100577589","phase-1-clinical-trial-of-pcv24-in-infants-aged-2-23-months-100577589","NCT06800261","Clinical Trial of PCV24 in Infants Aged 2-23 Months","A Randomized, Double-blind, Positive Controlled Phase Ib Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2 (Minimum 42 Days)-23 Months","Inclusion Criteria:\n\n1. Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months;\n2. Participants' guardian provides legal identity document and participants' vaccination record;\n3. Participants' guardian understands and voluntarily signs the informed consent form;\n4. Follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of invasive pneumococcal diseases or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of severe adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioneurotic edema, anaphylactic shock;\n4. Low birth weight (\\\u003C2.5kg), or premature infant (gestation weeks \\\u003C 37 weeks) (applies to infants younger than 12 months);\n5. History of abnormal labor during delivery (planned cesarean section is excluded), history of asphyxia rescue and nervous system damage (applies to infants younger than 12 months);\n6. Congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n7. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases (e.g. congenital heart disease), hematological diseases (e.g. severe anemia), liver and kidney diseases, digestive diseases, respiratory diseases (such as active tuberculosis), malignant tumors and major functional organ transplantation history;\n8. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n9. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets level), potential bleeding (history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture).\n10. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions, but febrile convulsion is not an exclusion criteria ) or mental illness or have a family history of such diseases.\n11. Consecutively received immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or other immunoregulatory therapies, or cytotoxic therapy over 14 days within 6 months before vaccination, or plans to receive such therapies during the study.\n12. Received blood products prior to enrollment within 3 months prior to enrollment, or plans to receive such therapies during the study. Receipt of Hepatitis B immunoglobulin one month prior to enrollment is an exception.\n13. Received other investigational drugs or vaccines within 30 days prior to enrollment, or plan to receive such drugs or vaccines during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment, known or potentially active infection;\n17. Axillary temperature≥ 37.3 Degree Celsius before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.","23 Months",{"count":74,"type":20},180,[76],"PHASE1","A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.\n\nThe objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.",[79],"Pneumococcal Infectious Disease","RECRUITING","2026-01-26",{"date":83,"type":31},"2026-01-28",{"date":85,"type":31},"2025-05-08",{"date":87,"type":20},"2026-06",{"name":37,"class":38},2,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":47,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":64},"100563557","phase-3-clinical-trial-of-13-valent-pneumococcal-conjugate-vaccine-100563557","NCT06617715","Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","A Phase Ⅲ Clinical Study to Evaluate the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Healthy Infants","Inclusion Criteria:\n\n1. Healthy infants or children who are aged 2 months (at least 6 weeks), 7-11 months, 12-23 months and 2-5 years (before the 6th birthday);\n2. Participants' guardians provide legal identity document and participants' vaccination record;\n3. Participants' guardians understand and voluntarily sign the informed consent form;\n4. Participants' guardians can follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of bacterial pneumonia or invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of allergy or adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioedema and abdominal pain;\n4. History of dystocia, asphyxia rescue and nervous system damage at birth for infants under 2 years of age;\n5. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, history of asthma;\n6. Autoimmune diseases (such as systemic lupus erythematosus), immunodeficiency diseases or immunosuppressive diseases (such as AIDS, organ transplantation);\n7. Severe cardiovascular diseases, diabetes, liver diseases, kidney diseases, malignant tumours.\n8. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions) or mental illness or have a family history of such diseases.\n9. History of thyroidectomy, asplenia, functional asplenia; asplenia or splenectomy caused by any reasons;\n10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets level), history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture.\n11. Consecutively received ≥14 days of corticosteroid, any other immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or cytotoxic therapy prior to enrollment for infants aged 6 weeks to 2 months or within 6 months prior to enrollment for children aged 7 months to 5 years.\n12. Received blood products prior to enrollment for children aged 2 months or within 3 months prior to enrollment for children aged 7 months to 5 years. Receipt of Hepatitis B immunoglobulin one month prior to enrollment is an exception.\n13. Received other investigational drugs within 60 days prior to enrollment, or plan to receive such drugs during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated or other vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment;\n17. Had fever (axillary temperature≥ 37.3 Degree Celsius) before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.","6 Weeks","5 Years",{"count":100,"type":20},3080,[23],"A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.",[79],{"date":83,"type":31},{"date":106,"type":31},"2024-10-23",{"date":108,"type":20},"2026-07-30",{"name":37,"class":38},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":47,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100621737","phase-1-phase-ia-clinical-trial-of-group-acyw135x-meningococcal-conjugate-vaccine-100621737","NCT07374510","Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine","An Open-Label Combined Randomized, Blinded, Placebo- and Active-Controlled Phase Ia Clinical Trial: Evaluate the Safety and Immunogenicity of the Group ACYW135X Meningococcal Conjugate Vaccine in Individuals Aged 2 to 59 Years","Inclusion Criteria:\n\n* Healthy participants aged 2 to 59 years;\n* The participant and\u002For their legal guardian can understand and voluntarily sign the informed consent form (for participants aged 8 to 17 years, the form must be signed jointly by the participant and their legal guardian);\n* Be willing and able to comply with all visit schedules, sample collection procedures, vaccination protocols and other trial-related requirements, and maintain contact at any time during the study period;\n* Provide valid legal identification documents of the participant and\u002For their legal guardian;\n* Participants of childbearing potential and their sexual partners shall voluntarily adopt effective contraceptive measures from the date of signing the informed consent form until 3 months after the administration of the investigational vaccine, with no plans for sperm or egg donation during this period.\n\nExclusion Criteria:\n\n* History of meningococcal disease;\n* History of asthma; history of hypersensitivity to any vaccine or vaccine components (including serogroup A\u002FC\u002FY\u002FW135\u002FX meningococcal capsular polysaccharide, mannitol, sucrose, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium chloride, and water for injection), manifested as symptoms such as urticaria, dyspnea, or angioedema; or history of other severe adverse reactions following previous vaccination;\n* For children aged 2 to 6 years: history of previous vaccination with group ACYW135 meningococcal polysaccharide vaccine; or history of previous vaccination with any meningococcal conjugate vaccine other than group AC meningococcal conjugate vaccine; an interval of ≤ 12 months from the last dose of group A or group AC meningococcal polysaccharide vaccine or group AC meningococcal conjugate vaccine; history of vaccination with meningococcal conjugate vaccine since reaching 1 year of age. No vaccination history restrictions apply to participants aged 7 to 59 years;\n* Presence of autoimmune diseases or immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n* Presence of coagulation disorders (e.g., coagulation factor deficiency, thrombocytopathy), or a history of significant bleeding, hematoma, or ecchymosis following previous intramuscular injection or venipuncture;\n* History of severe diseases or current diagnosis of severe chronic diseases (including but not limited to severe cardiovascular diseases, uncontrolled hypertension, hematological diseases, hepatic and renal diseases, gastrointestinal diseases, respiratory diseases, malignant tumors, and history of major organ transplantation);\n* Presence of severe congenital malformations, genetic defects, or malnutrition;\n* Presence or history of severe neurological diseases (epilepsy, convulsions, or seizures) or psychiatric disorders, or a family history of psychiatric disorders;\n* Chronic alcohol abuse \\[weekly alcohol consumption \\> 14 standard drinks (1 standard drink = 14 grams of 100% alcohol ≈ 360 mL beer, 150 mL wine, or 45 mL distilled spirits\u002Fliquor)\\] or a history of substance abuse (repeated and excessive use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.);\n* Receipt of immunosuppressive therapy or other immunomodulatory therapy for ≥ 14 days within the past 6 months (prednisone ≥ 20 mg\u002Fday or ≥ 2 mg\u002Fkg\u002Fday, or its equivalent dose); receipt of cytotoxic therapy; or planned receipt of such therapies during the study period;\n* Receipt of blood products within 3 months prior to the administration of the investigational vaccine;\n* Receipt of other investigational drugs or vaccines within 3 months prior to the administration of the investigational vaccine, or planned receipt of such drugs or vaccines during the study period;\n* Receipt of live attenuated vaccines or nucleic acid vaccines within the past 14 days, or receipt of subunit vaccines or inactivated vaccines within the past 7 days;\n* Participants who are breastfeeding, pregnant, or planning to become pregnant within 3 months after vaccination in this trial;\n* Presence of any acute diseases or acute exacerbation of chronic diseases within the past 7 days, or known or suspected active infections;\n* Clinically significant abnormal findings in laboratory tests：\n\n  1. Hematological parameters: white blood cell count, hemoglobin, platelet count;\n  2. Biochemical parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), blood glucose;\n  3. Urinalysis parameters: urine protein (PRO);\n* Axillary temperature \\> 37.0℃ prior to vaccination, or other vital sign measurements beyond the reference range;\n* Presence of skin damage, inflammation, ulceration, rash, or scarring at the intended injection site that may interfere with vaccination or observation of local reactions;\n* Any other factors that, in the investigator's judgment, render the participant unsuitable for participation in this clinical trial.","2 Years","59 Years",{"count":120,"type":20},150,[76],"This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal Conjugate Vaccine. This study is planned to enroll 150 participants in total, with healthy individuals aged 2 to 59 years as participants. Among them, participants aged 18 to 59 years and 7 to 17 years will be assigned to the open-label design arm, while participants aged 4 to 6 years will be assigned to the randomized, blinded, placebo-controlled design arms.",[124],"Meningococcal Meningitis",[126,127,128],"ACYW135X","vaccine","phase 1","2026-01-20",{"date":83,"type":31},{"date":132,"type":20},"2026-01-21",{"date":134,"type":20},"2026-11-30",{"name":37,"class":38},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":98,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100616056","phase-2-clinical-trial-of-pcv24-in-infants-and-children-aged-2-months-to-5-years-100616056","NCT07300644","Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2 Months (Minimum 42 Days) to 5 Years","Inclusion Criteria:\n\n1. Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months, and 2-5 years;\n2. The participants' guardian provides a legal identity document and the participants' vaccination record;\n3. The participant's guardian understands and voluntarily signs the informed consent form;\n4. Follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of invasive pneumococcal diseases or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of severe adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioneurotic edema, anaphylactic shock;\n4. Low birth weight (\\\u003C2.5kg), or premature infant (gestation weeks \\\u003C 37 weeks) (applies to infants younger than 12 months);\n5. History of abnormal labor during delivery (planned cesarean section is excluded), history of asphyxia rescue and nervous system damage (applies to infants younger than 12 months);\n6. Severe congenital malformations or developmental disorders, genetic defects, or malnutrition;\n7. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases (e.g. congenital heart disease), hematological diseases (e.g. severe anemia), liver and kidney diseases, digestive diseases, respiratory diseases (such as active tuberculosis), malignant tumors and major functional organ transplantation history;\n8. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n9. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelet levels);\n10. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions, but a febrile convulsion is not an exclusion criteria ) or mental illness, or have a family history of such diseases;\n11. Consecutively received immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or other immunoregulatory therapies, or cytotoxic therapy over 14 days within 6 months before vaccination, or plans to receive such therapies during the study;\n12. Receipt of immunoglobulins or other blood products within 3 months prior to administration of the investigational vaccine (except for hepatitis B immunoglobulin or rabies immunoglobulin used within 1 month), or planned use of such products during the study period;\n13. Received other investigational drugs or vaccines within 30 days prior to enrollment, or plan to receive such drugs or vaccines during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment, known or potentially active infection;\n17. Axillary temperature≥ 37.3 Degree Celsius before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.",{"count":144,"type":20},420,[146],"PHASE2","A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.\n\nThe objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.",[79],[150,151],"PCV24","Phase 2","2025-12-17",{"date":154,"type":31},"2025-12-24",{"date":156,"type":31},"2025-11-25",{"date":158,"type":20},"2027-12",{"name":37,"class":38},3,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":47,"sex":16,"minAge":97,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":64},"100590427","phase-2-phaseclinical-trial-of-oral-hexavalent-reassortant-rotavirus-attenuated-live-vaccine-vero-cells-100590427","NCT06967272","PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","Evaluating the Immunogenicity and Safety of the Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) in Healthy Infants Via a Randomized, Double-blind, Active-controlled Phase II Clinical Trial.","Inclusion Criteria:\n\n1. Healthy infants aged 6 to 12 weeks.\n2. The legal guardian(s) is\u002Fare capable of understanding and voluntarily signing the informed consent form.\n3. The legal guardian(s) is\u002Fare willing and able to comply with all follow-up visits, sample collection, vaccination, and other study procedures.\n4. Able to provide valid legal identification documents.\n\nExclusion Criteria:\n\n1. Previous vaccination with any rotavirus vaccine.\n2. History of rotavirus infection.\n3. Gestational age \\\u003C37 weeks or ≥42 weeks at birth.\n4. History of dystocia, neonatal asphyxia requiring resuscitation, or neurological impairment at birth.\n5. Known hypersensitivity to any vaccine component (e.g., urticaria, dyspnea, angioedema).\n6. Current diarrhea, vomiting, or other gastrointestinal disorders; gastroenteritis or any acute\u002Fchronic illness exacerbation within 7 days prior to vaccination; ongoing antibiotic\u002Fantiviral therapy.\n7. History of intussusception or chronic gastrointestinal diseases, including congenital malformations predisposing to intussusception (e.g., Meckel's diverticulum).\n8. Congenital malformations, developmental disorders, genetic defects, severe malnutrition, malignancies, or significant chronic conditions (e.g., Down syndrome, diabetes, sickle cell anemia, neurological disorders, Guillain-Barré syndrome).\n9. Autoimmune or immunodeficiency diseases (including but not limited to asplenia, functional asplenia, HIV infection).\n10. Household members with immunodeficiency\u002Fimmunosuppression or undergoing\u002Fscheduled for immunosuppressive\u002Fcytotoxic therapy.\n11. Coagulation disorders (e.g., clotting factor deficiencies, platelet abnormalities).\n12. Immunosuppressive therapy for ≥14 days post-birth (prednisone ≥2mg\u002Fkg\u002Fday or equivalent), immunomodulatory\u002Fcytotoxic therapy, or planned use during the study.\n13. History of severe neurological\u002Fpsychiatric disorders (e.g., epilepsy, non-febrile seizures, convulsions) or relevant family history.\n14. Postnatal administration of immunoglobulins\u002Fblood products (except hepatitis B immunoglobulin) or planned use during the study.\n15. Previous participation in other investigational drug\u002Fvaccine studies or planned use during this study.\n16. Receipt of live-attenuated vaccines within 14 days or subunit\u002Finactivated vaccines within 7 days prior to enrollment.\n17. Axillary temperature ≥38.0°C within the past 3 days.\n18. Fever on scheduled vaccination day (axillary temperature \\>37.0°C; measured ≥30 minutes post-feeding).\n19. Currently or planning to participate in other vaccine or drug clinical trials.\n20. Any other factors that the investigator deems unsuitable for participation in the clinical trial.","12 Weeks",{"count":170,"type":20},400,[146],"The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.",[174],"Rotavirus Gastroenteritis",[176,177,178,179,180,181],"Phase II","Immunogenicity","Safety","Randomized Controlled Trial","Rotavirus gastroenteritis","Vaccine","2025-08-18",{"date":184,"type":31},"2025-08-22",{"date":186,"type":31},"2025-01-20",{"date":188,"type":20},"2026-11-15",{"name":37,"class":38},""]